[Recent issues and prospects of the treatment of aplastic anemia].
Shinji
S
Nakao
D000741:Anemia, Aplastic / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D000818:Animals; D000961:Antilymphocyte Serum / Q000008:administration & dosage* / Q000009:adverse effects; D001565:Benzoates / Q000008:administration & dosage* / Q000494:pharmacology; D015415:Biomarkers / Q000097:blood; D016572:Cyclosporine / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004359:Drug Therapy, Combination; D004854:Herpesvirus 4, Human; D006801:Humans; D006834:Hydrazines / Q000008:administration & dosage* / Q000494:pharmacology; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D008232:Lymphoproliferative Disorders / Q000209:etiology / Q000517:prevention & control / Q000821:virology; D011239:Prednisolone / Q000008:administration & dosage; D011720:Pyrazoles / Q000008:administration & dosage* / Q000494:pharmacology; D053628:Receptors, Thrombopoietin / Q000819:agonists; D012306:Risk; D012720:Severity of Illness Index; D013926:Thrombopoietin / Q000097:blood
D000961:Antilymphocyte Serum; D001565:Benzoates; D015415:Biomarkers; D006834:Hydrazines; D007166:Immunosuppressive Agents; D011720:Pyrazoles; D053628:Receptors, Thrombopoietin; D016572:Cyclosporine; D013926:Thrombopoietin; D011239:Prednisolone; C520809:eltrombopag